After cutting his 2021 and 2022 financial projections, Mr. Lynk dropped his target for Xebec shares to $6 from $10. The average is $8.66.

Elsewhere, Raymond James’ David Quezada lowered the stock to “outperform” from “strong buy” with a $7.50 target, down from $14.50.

“While the news is clearly disappointing, the forward-looking impact is mitigated by increased diversification in the business from recent acquisitions. We believe the share price reaction is overdone,” he said.

TD Securities analyst Aaron MacNeil cut his target to $10 from $17.50 with a “buy” rating, while National Bank Financial’s Rupert Merer lowered his target to $6 from $7 with a “sector perform” recommendation.

I rest my case